GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
By Dennis Thompson HealthDay Reporter
TUESDAY, May 13, 2025 — Cutting-edge weight-loss drugs like Ozempic/Wegovy can cut alcohol intake dramatically in a short amount of time, a new study says.
People taking semaglutide or liraglutide reduced their alcohol consumption by two-thirds within four months, according to results recently published in the journal Diabetes, Obesity and Metabolism.
These glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.
GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to cravings for alcohol, said senior researcher Dr. Carel le Roux, chair of experimental pathology at University College Dublin in Ireland.
“Thus, patients report the effects are ‘effortless’,” allowing them to cut drinking with little conscious effort, Le Roux said in a news release.
Drinking accounts for nearly 5% of deaths worldwide, researchers noted. Treatments for problem drinking can be very successful in the short-term but about 70% of patients relapse within a year.
Early animal studies have indicated that GLP-1 drugs can help cut alcohol cravings, but studies involving humans are only starting to emerge, researchers said.
For this study, researchers tracked the health of 262 people who were clinically overweight or obese and being treated for excess weight at a Dublin clinic. All the patients had been prescribed either semaglutide or liraglutide for weight loss.
About 12% never drank; 20% drank rarely; and 68% drank regularly, researchers said.
Among regular drinkers, alcohol intake decreased by 68% within four months of starting GLP-1 drugs, results show. Researchers said that’s comparable to results from nalmefene, a drug used to treat alcoholism in Europe.
“GLP-1 analogues have been shown treat obesity and reduce the risk of multiple obesity-related complications,” Le Roux said. “Now, the beneficial effects beyond obesity, such as on alcohol intake, are being actively studied, with some promising results.”
However, researchers noted that the study involved a small number of patients and did not compare them against a control group not taking GLP-1 drugs.
Along with earlier publication of the findings, researchers presented them Friday at a meeting of the European Association for the Study of Obesity in Malaga, Spain.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-14 00:00
Read more

- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
- Bilateral Salpingo-Oophorectomy Beneficial in BRCA1/2 Carriers With Personal History of Breast Cancer
- FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic
- More Kids Without Asthma Inhaler After Flovent Taken Off Market
- Conversion Therapy Harms Heart Health
- Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions